Abstract: Objective  To observe the clinical efficacy and adverse reactions of apatinib for secondline treatment failure of advanced nonsmall cell lung cancer. Methods  Thirty patients received treatment of  apatinib at a dose of 500 mg/day for two weeks， then increased to 750 mg/day if they could tolerate and maintain the therapy. The efficacy was evaluated by the imaging and testing tumor such as markers including CEA， CA199， CA125 and SCC. Results  The clinical evaluation of the patients were complete remission 0 case， partial remission 9 cases， steady 16 cases， progess  3 cases，2 cases terminated the treatment due to adverse reactions， and the objective response rate was 32.1%(9/28)，disease control rate was 89.3%(25/28）.After four weeks′  treatment， CEA， CA199， CA125 and SCC were significantly reduced than the previous（P<0.05）.The effective rate on the prognosis of different metastatic sites were no significant difference （P>0.05）.The main toxicities were hypertension， oral mucositis and poor appetite（33.3%，30.0% and 23.3%）.Conclusion  The treatment of apatinib in secondline  treatment  failure of advanced nonsmall cell lung cancer  has better clinical efficacy， and toxicity could be controlled， so it was worth evaluating the longterm efficacy of apatinib for advanced nonsmall cell lung cancer.

Key words: apatinib, carcinoma, nonsmall cell lung, efficacy, adverse effects